| Net income | 43.9M |
| Depreciation, amortization and accretion | 106.4M |
| Non-cash asset impairment charges | 0 |
| Equity in income of Evangeline | -800K |
| Distribution received from Evangeline | 1.5M |
| Gains from asset sales and related transactions | -500K |
| Deferred income tax expense | 500K |
| Net effect of changes in operating accounts (see Note 17) | -18.7M |
| Cash flows provided by operating activities | 132.3M |
| Capital expenditures | -847.9M |
| Contributions in aid of construction costs | 4.9M |
| Proceeds from sale of assets and related transactions | 100K |
| Other, including loans to EPO (see Note 13) | 0 |
| Cash used in investing activities | -842.9M |
| Borrowings under bank agreements | 419M |
| Repayments of debt under bank agreements | -57.5M |
| Cash distributions to our unitholders and general partner | -53.1M |
| Cash distributions to EPO as noncontrolling interest | -62.5M |
| Cash contributions from EPO as noncontrolling interest | 449.4M |
| Net cash proceeds from the issuance of common units | 1.5M |
| Cash provided by financing activities | 696.8M |
| Net changes in cash and cash equivalents | -13.8M |
| Cash and cash equivalents, January 1 | 32.4M |
| Cash and cash equivalents, June 30 | 18.6M |